Strategic Regulatory Planning Flashcards

A company wants to expand an approved drug's indication. Which US regulatory mechanism most strategically minimizes development burden if supportive data already exists?

Answer: Submit a Prior Approval Supplement (PAS) or efficacy supplement to the existing NDA

An efficacy supplement (Prior Approval Supplement) to an existing NDA is the standard and most efficient pathway to expand approved indications using existing or new clinical data.

What is the role of a Target Product Profile (TPP) in regulatory strategy?

Answer: It defines the desired product attributes that drive regulatory, clinical, and CMC development decisions

The TPP articulates the minimum and ideal characteristics of the final product, aligning all development functions — including regulatory — around shared goals from the outset.

Under FDA's rolling review process, what is the primary strategic benefit for sponsors?

Answer: Sponsors can submit completed sections of the NDA/BLA as data become available, potentially shortening overall review time

Rolling review allows FDA to begin evaluating completed modules before the full dossier is submitted, compressing the review timeline for products with expedited designations.

When assessing regulatory risk in a strategic plan, which factor would MOST increase risk for a first-in-class drug?

Answer: Lack of regulatory precedent for the mechanism of action and uncertainty about acceptable endpoints

First-in-class drugs face heightened regulatory risk because there is no precedent for acceptable endpoints, biomarkers, or safety expectations, requiring more agency interaction and potentially novel approaches.

Which international regulatory framework specifically harmonizes technical requirements for pharmaceuticals to reduce global development redundancy?

Answer: ICH (International Council for Harmonisation)

ICH harmonizes pharmaceutical technical requirements across the US, EU, and Japan through guidelines covering quality, safety, efficacy, and multidisciplinary topics.

A regulatory team must decide between a single global clinical study or separate regional studies. What is the primary regulatory consideration favoring a global study?

Answer: A single study with diverse populations can support submissions across multiple regions, avoiding bridging studies

A well-designed global trial with diverse populations can satisfy multiple regulatory bodies simultaneously, avoiding the need for separate regional bridging studies and accelerating worldwide approval.

Which metric is most important to track during strategic regulatory planning to ensure alignment with corporate timelines?

Answer: Projected submission date versus regulatory milestone critical path

The projected submission date relative to the regulatory critical path determines whether development activities will support corporate launch commitments and revenue projections.